It is not surprising that a new study on the relationship between income and longevity in the United States concludes that life expectancy increased with income. However, the study did shed light on the variabilities in the income-longevity relationship.
It is not surprising that a new study on the relationship between income and longevity in the United States concludes that life expectancy increased with income. However, the study did shed light on the variabilities in the income-longevity relationship.
The study used income data for the US population that were obtained from 1.4 billion deidentified tax records of individuals ages 40 to 76 years between 1999 and 2014. Social Security Administration death records provided mortality data. These data were used to estimate race- and ethnicity-adjusted life expectancy at 40 years of age by household income percentile, sex, and geographic area, and to analyze factors associated with differences in life expectancy. The main findings were as follows:
The strongest pattern in the data was that low-income individuals tend to live longest and have more healthy behaviors in cities with highly educated populations, high incomes, and high levels of government expenditures such as New York City and San Francisco. In these cities, life expectancy for people in the bottom 5% of income distribution was approximately 80 years; in contrast, in cities such as Detroit, Michigan, the expected age at death for those in the bottom 5% was approximately 75 years.
Low-income individuals living in cities with highly educated populations and high incomes also had the largest gains in life expectancy during the 2000s, the authors said.
The researchers conclude that reducing gaps in longevity may require local policy responses, and that health professionals make targeted efforts to improve health among low-income populations with policy interventions focusing on changing health behaviors among low-income people. Tax policies and other local public policies may play a role in inducing such changes, they advise.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
ICS Use Tied to Fewer Exacerbations in Patients With Bronchiectasis and Elevated Blood Eosinophils
June 6th 2025Inhaled corticosteroid (ICS) use was common among patients with bronchiectasis and was associated with reduced exacerbations and hospitalizations in those with elevated blood eosinophil counts.
Read More
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More